Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study

Lee, Fei Yee; Islahudin, Farida; Nasiruddin, Aina Yazrin Ali; Gafor, Abdul Halim Abdul; Wong, H.S.; Bavanandan, Sunita; Saffian, Shamin Mohd; Redzuan, Adyani Md; Tahir, Nurul Ain Mohd; Makmor‐Bakry, Mohd

doi:10.3390/jpm11040252

Cited by 6 publications

(6 citation statements)

References 37 publications

(23 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venous blood was collected from patients and DNA was extracted using the DNeasy ® Blood and Tissue extraction kit (Qiagen, Hilden, Germany). A polymerase chain reaction of the region encompassing the CYP3A5*3 gene polymorphism was performed using the TopTaq Mastermix Kit (Qiagen, Hilden, Germany), followed by direct sequencing using the BigDye ® Terminator version 3.1 cycle sequencing kit, which was run on a 96-capillary 3730xl DNA Analyzer (developed by Applied Biosystem, United States and produced by Thermo Fisher Scientific) ( Boutin et al, 2000 ; Lee et al, 2021a ). Other gene polymorphisms of the CYP3A5 gene were not assessed, given the low prevalence of other polymorphisms in South East and East Asian populations ( Dorji et al, 2019 ).…”

Section: Methodsmentioning

confidence: 99%

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients

et al. 2022

Self Cite

View full text Add to dashboard Cite

Chronic kidney disease (CKD) patients may be more susceptible to adverse drug reactions (ADRs), given their complex medication regimen and altered physiological state driven by a decline in kidney function. This study aimed to describe the relationship between CYP3A5*3 polymorphism and the ADR of antihypertensive drugs in CKD patients. This retrospective, multi-center, observational cohort study was performed among adult CKD patients with a follow-up period of up to 3 years. ADRs were detected through medical records. CYP3A5*3 genotyping was performed using the direct sequencing method. From the 200 patients recruited in this study, 33 (16.5%) were found to have ADRs related to antihypertensive drugs, with 40 ADRs reported. The most frequent ADR recorded was hyperkalemia (n = 8, 20.0%), followed by bradycardia, hypotension, and dizziness, with 6 cases (15.0%) each. The most common suspected agents were angiotensin II receptor blockers (n = 11, 27.5%), followed by angiotensin-converting enzyme inhibitors (n = 9, 22.5%). The CYP3A5*3 polymorphism was not found to be associated with antihypertensive-related ADR across the genetic models tested, despite adjustment for other possible factors through multiple logistic regression (p > 0.05). After adjusting for possible confounding factors, the factors associated with antihypertensive-related ADR were anemia (adjusted odds ratio [aOR] 5.438, 95% confidence interval [CI]: 2.002, 14.288) and poor medication adherence (aOR 3.512, 95% CI: 1.470, 8.388). In conclusion, the CYP3A5*3 polymorphism was not found to be associated with ADRs related to antihypertensives in CKD patients, which requires further verification by larger studies.

show abstract

Section: Methodsmentioning

confidence: 99%

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…For ACEIs and ARBs, there was no influence of CYP3A5*3 on pharmacogenetics in CKD ( Lee et al, 2021 ).…”

Section: Influence Of Gene Polymorphisms On Response To Raas Inhibitionmentioning

confidence: 99%

Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review

Alshahrani

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Chronic kidney disease presents a health challenge that has a complex underlying pathophysiology, both acquired and inherited. The pharmacotherapeutic treatment options available today lower the progression of the disease and improve the quality of life but cannot completely cure it. This poses a challenge to the healthcare provider to choose, from the available options, the best way to manage the disease as per the presentation of the patient. As of now, the recommended first line of treatment to control the blood pressure in chronic kidney disease is the administration of renin–angiotensin–aldosterone system modulators. These are represented mainly by the direct renin inhibitor, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. These modulators are varied in their structure and mechanisms of action, hence showing varying treatment outcomes. The choice of administration of these modulators is determined by the presentation and the co-morbidities of the patient, the availability and affordability of the treatment option, and the expertise of the healthcare provider. A direct head-to-head comparison between these significant renin–angiotensin–aldosterone system modulators is lacking, which can benefit healthcare providers and researchers. In this review, a comparison has been drawn between the direct renin inhibitor (aliskiren), angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers. This can be of significance for healthcare providers and researchers to find the particular loci of interest, either in structure or mechanism, and to intervene as per the case presentation to obtain the best possible treatment option.

show abstract

“…These studies [12][13][14] also demonstrated the modifiable factors associated with CKD which included alcohol consumption, overweight, obesity, prediabetes, diabetes mellitus and hypertension. Studies conducted in Malaysia also examined the non-modifiable [15], modifiable [7] factors and the interactions between these factors [16] with CKD. One modifiable factor is knowledge, and it is agreed that knowledge is a crucial step towards preventing a disease [17,18].…”

Section: Introductionmentioning

confidence: 99%

Knowledge of chronic kidney disease among undergraduate and postgraduate students in a public university in Klang Valley, Malaysia: A cross sectional study

et al. 2022

Self Cite

View full text Add to dashboard Cite

The prevalence of chronic kidney disease (CKD) risk factors such as diabetes mellitus, hypertension, and obesity among the young Malaysians are increasing. Understanding the factors associated with CKD knowledge could assists healthcare providers to design health education programmes. There are scarce local studies on CKD knowledge and its associated factors among university students. This subpopulation comprises of young people with diverse background and characteristics. This study was aimed to assess the CKD knowledge and its associated factors among university students. A cross-sectional study was conducted among Universiti Kebangsaan Malaysia students from July 2020 to August 2020. A convenience sampling method was applied. All students were invited to complete an online survey using Google Forms that were sent to their email. The survey consisted of questions related to their sociodemographic, socioeconomics, university programme enrolled, medical history, lifestyle characteristics and CKD knowledge. The data were analysed using SPSS Statistics 26.0. Multiple logistic regression analysis was performed to identify the final associated factors after controlling for confounders. A total of 3074 students participated and 32.6% of them had below average CKD knowledge. Students of male gender, enrolment in undergraduate programmes and non-health-related faculties/institutes were more likely to have below average CKD knowledge. Students who are Chinese, from high monthly household income family and with family history of CKD were less likely to have below average CKD knowledge. Almost one-third of the students had below average CKD knowledge. The six associated factors with CKD knowledge were non-modifiable. Of the six factors, three were associated with students being more likely to have below average CKD knowledge; another three were associated with students being less likely to have below average CKD knowledge. Future health education programmes to enhance CKD knowledge should be designed focusing on students who are more likely to have below average CKD knowledge.

show abstract

Effects of CYP3A5 Polymorphism on Rapid Progression of Chronic Kidney Disease: A Prospective, Multicentre Study

Cited by 6 publications

References 37 publications

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients

Adverse Drug Reactions of Antihypertensives and CYP3A5*3 Polymorphism Among Chronic Kidney Disease Patients

Renin–angiotensin–aldosterone pathway modulators in chronic kidney disease: A comparative review

Knowledge of chronic kidney disease among undergraduate and postgraduate students in a public university in Klang Valley, Malaysia: A cross sectional study

Contact Info

Product

Resources

About